Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial
Auteurs : Nawal Al Kaabi, MBBS; Yuntao Zhang, PhD; Shengli Xia, BSc; Yunkai Yang, MSc; Manaf M. Al Qahtani, MD; Najiba Abdulrazzaq, MBBS; Majed Al Nusair, MD; Mohamed Hassany, MD; Jaleela S. Jawad, MBBS; Jehad Abdalla, MBBS; Salah Eldin Hussein, MBBS; Shamma K. Al Mazrouei, MBBS; Maysoon Al Karam, MBBS; Xinguo Li, MSc; Xuqin Yang, MSc; Wei Wang, MSc; Bonan Lai, MSc; Wei Chen, MSc; Shihe Huang, PhD; Qian Wang, MSc; Tian Yang, BSc; Yang Liu, MSc; Rui Ma, MSc; Zaidoon M. Hussain, MD; Tehmina Khan, MD; Mohammed Saifuddin Fasihuddin, BSc; Wangyang You, BSc; Zhiqiang Xie, MSc; Yuxiu Zhao, MSc; Zhiwei Jiang, PhD; Guoqing Zhao, PhD; Yanbo Zhang, MSc; Sally Mahmoud, PhD; Islam ElTantawy, BSc; Peng Xiao, MSc; Ashish Koshy, MSc; Walid Abbas Zaher, PhD; Hui Wang, BSc; Kai Duan, PhD; An Pan, PhD; Xiaoming Yang, MD
Revue : The Journal of the American Medical Association (JAMA)
Date : publication en ligne le 26 mai 2021
This prespecified interim analysis of a randomized clinical trial included 40 382 participants who received at least 1 dose of a 2-dose inactivated vaccine series developed from either SARS-CoV-2 WIV04 (5 µg/dose) or HB02 (4 µg/dose) strains or an aluminum hydroxide–only control, with a primary end point of the incidence of symptomatic COVID-19 at least 14 days after the second injection. The efficacy for the 2 vaccines, compared with an aluminum hydroxide–only control, was 72.8% in the WIV04 group and 78.1% in the HB02 group; both comparisons were statistically significant.
Source : Nawal Al Kaabi, Yuntao Zhang, Shengli Xia [et al.], “Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial”, Journal of the American Medical Association (JAMA), publication en ligne le 26/05/2021. DOI : 10.1001/jama.2021.8565 (consulté le 27/05/2021).
Photo “à la une” : Figure 3. Common Adverse Reactions and Grades Within 7 Days After 2 Doses in the Safety Analysis Set © DR
OpenEdition vous propose de citer ce billet de la manière suivante :
Admin IAO (27 mai 2021). Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. Asie Orientale et Coronavirus. Consulté le 5 novembre 2024 à l’adresse https://doi.org/10.58079/n84p